Wednesday, May 16, 2012
Galectin Therapeutics Inc., of Newton, Mass., said the first patient was dosed in a Phase I/II trial testing GM-CT-01, its carbohydrate-based galectin inhibitor, in combination with a peptide vaccine furnished by the Ludwig Institute for Cancer Research in advanced metastatic melanoma. The primary endpoint is partial or complete response.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.